US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Original Article: FDA approves heart protection label change for Repatha
NEXT ARTICLE